World Conference on Lung Cancer 2020 News

A Special Edition of IASLC Lung Cancer News
World Conference on Lung Cancer 2020 Landing Page Banner Image

In Focus

World Conference on Lung Cancer 2020 News Flipbook Cover Image

Explore all WCLC News Articles.

Figure 1: Deeper Understanding of EGFR Mutation Subgroups Will Further Personalize Treatment for NSCLC

Deeper Understanding of EGFR Mutation Subgroups Will Further Personalize Treatment for NSCLC

New insights into the types of EGFR mutations that can arise in NSCLC may help guide decisions about the most appropriate targeted drugs for individual patients.

Figure 1: Improved Screening Uptake Could Help Double Lung Cancer Survival by 2025

Improved Screening Uptake Could Help Double Lung Cancer Survival by 2025

Between 60% and 65% of patients with lung cancer receive their diagnoses at stage III or IV, meaning that one-third are unaware of their disease when radical surgery, either alone or with adjuvant therapy, could be curative.

Envisioning A Tobacco-Free Generation

FIgure 1: Envisioning A Tobacco-Free Generation

Although ads to promote tobacco products have been curtailed during the past few decades, cancer from using tobacco products still kills more than 8 million people each year, according to the World Health Organization.

Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC

Figure 1: Sotorasib Shows Early Activity Against KRASG12C Mutant NSCLC

The first-in-class KRAS G12C inhibitor sotorasib has demonstrated early, deep, and durable responses in the treatment of advanced NSCLC with KRAS G12C mutations, according to results from the registrational phase II CodeBreaK 100 trial.

Nivolumab Boosted Survival in Relapsed Mesothelioma

Figure: Nivolumab Boosted Survival in Relapsed Mesothelioma

Nivolumab significantly improved investigator-reported progression-free survival and overall survival compared with placebo in patients with relapsed malignant mesothelioma, according to preliminary results of the CONFIRM phase III trial presented during the Presidential Symposium.

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Figure 1: Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Evaluation of mRNA expression of selected genes to tailor adjuvant chemotherapy did not improve survival outcomes in patients with resected stage II-III NSCLC, according to results of the ITACA study, presented during the Presidential Symposium.

Image
CME CREDIT CLAIM FOR WCLC

If you require CME credits, please fill out the confirmation form that is available during or at the end of each session. You will only receive credits for the sessions for which you have completed the form. You can claim credits until March 30, 2021. 

CME Certificates will be automatically sent on April 12, 2021 to all delegates who completed the confirmation forms. 

A Certificate of Attendance will be sent to all registered non-physicians immediately following the conference. 

For further information, you may also refer to the Conference website
 

Twitter block

More WCLC-Related News